Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.
Meeson will bring his expertise to Axplora’s global footprint of 10 sites on 3 continents while continuing to amplify the group’s capabilities and strengths.
Technological advancements, global market dynamics, and patient-centric approaches are all factors driving the transformation of the parenteral drug market.
Jeff Clement, Executive Director, Technical Sales – Development and Manufacturing, PCI Pharma Service
100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
Its subsidiary, Humber Industrials Ltd., has reached an agreement to purchase Novartis UK's 170-acre API manufacturing plant site and assets in Grimsby, UK.